S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
Banking Nightmare (Ad)
Judge orders US to resume oil lease sales in North Dakota
Closing prices for crude oil, gold and other commodities
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
Banking Nightmare (Ad)
Judge orders US to resume oil lease sales in North Dakota
Closing prices for crude oil, gold and other commodities
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
Banking Nightmare (Ad)
Judge orders US to resume oil lease sales in North Dakota
Closing prices for crude oil, gold and other commodities
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
Banking Nightmare (Ad)
Judge orders US to resume oil lease sales in North Dakota
Closing prices for crude oil, gold and other commodities
NYSE:TDOC

Teladoc Health - TDOC Competitors

$25.03
+0.77 (+3.17%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$24.40
$25.11
50-Day Range
$23.53
$33.20
52-Week Range
$21.60
$77.50
Volume
2.67 million shs
Average Volume
3.44 million shs
Market Capitalization
$4.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.72

TDOC vs. HIMS, SGRY, HAE, MMSI, NEOG, ICUI, CERE, PINC, MDGL, and CERT

Should you be buying Teladoc Health stock or one of its competitors? The main competitors of Teladoc Health include Hims & Hers Health (HIMS), Surgery Partners (SGRY), Haemonetics (HAE), Merit Medical Systems (MMSI), Neogen (NEOG), ICU Medical (ICUI), Cerevel Therapeutics (CERE), Premier (PINC), Madrigal Pharmaceuticals (MDGL), and Certara (CERT). These companies are all part of the "medical" sector.

Teladoc Health vs.

Hims & Hers Health (NYSE:HIMS) and Teladoc Health (NYSE:TDOC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Teladoc Health received 640 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 64.73% of users gave Teladoc Health an outperform vote while only 33.33% of users gave Hims & Hers Health an outperform vote.

CompanyUnderperformOutperform
Hims & Hers HealthOutperform Votes
17
33.33%
Underperform Votes
34
66.67%
Teladoc HealthOutperform Votes
657
64.73%
Underperform Votes
358
35.27%

45.6% of Hims & Hers Health shares are held by institutional investors. Comparatively, 84.1% of Teladoc Health shares are held by institutional investors. 35.2% of Hims & Hers Health shares are held by company insiders. Comparatively, 1.6% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hims & Hers Health has a net margin of -12.47% compared to Teladoc Health's net margin of -567.53%. Teladoc Health's return on equity of -4.35% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Hims & Hers Health -12.47% -20.69% -17.39%
Teladoc Health -567.53% -4.35% -3.24%

Hims & Hers Health currently has a consensus price target of $11.55, indicating a potential upside of 15.15%. Teladoc Health has a consensus price target of $34.72, indicating a potential upside of 38.71%. Given Teladoc Health's higher probable upside, analysts plainly believe Teladoc Health is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hims & Hers Health
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Teladoc Health
0 Sell rating(s)
18 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.28

Hims & Hers Health has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

In the previous week, Teladoc Health had 4 more articles in the media than Hims & Hers Health. MarketBeat recorded 8 mentions for Teladoc Health and 4 mentions for Hims & Hers Health. Teladoc Health's average media sentiment score of 0.83 beat Hims & Hers Health's score of 0.38 indicating that Teladoc Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hims & Hers Health
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teladoc Health
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hims & Hers Health has higher earnings, but lower revenue than Teladoc Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hims & Hers Health$526.92 million3.97-$65.68 million-$0.32-31.34
Teladoc Health$2.41 billion1.69-$13.66 billion-$84.74-0.30

Summary

Teladoc Health beats Hims & Hers Health on 12 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TDOC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TDOC vs. The Competition

MetricTeladoc HealthOffices & clinics of medical doctors IndustryMedical SectorNYSE Exchange
Market Cap$4.07B$1.02B$4.37B$14.44B
Dividend YieldN/AN/A2.31%3.92%
P/E Ratio-0.30N/A152.9422.68
Price / Sales1.691.173,500.7910.89
Price / Cash0.3013.6719.8016.41
Price / Book1.762.354.566.83
Net Income-$13.66B-$1.76B$115.26M$867.88M
7 Day Performance2.20%0.11%1.22%2.52%
1 Month Performance-5.51%-22.50%-6.49%-5.27%
1 Year Performance-67.14%-45.29%-15.26%-14.47%

Teladoc Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIMS
Hims & Hers Health
2.0772 of 5 stars
$10.03
+1.2%
$11.55
+15.2%
+87.5%$2.09B$526.92M-31.34398Short Interest ↑
SGRY
Surgery Partners
2.2024 of 5 stars
$32.70
+4.3%
$42.00
+28.4%
-41.4%$4.12B$2.54B-56.3812,200Positive News
Gap Up
HAE
Haemonetics
2.5546 of 5 stars
$79.50
+0.5%
$101.00
+27.0%
+29.7%$4.01B$993.20M42.972,821
MMSI
Merit Medical Systems
2.2115 of 5 stars
$72.42
+0.3%
$76.33
+5.4%
+10.7%$4.15B$1.15B55.716,846Positive News
NEOG
Neogen
1.1078 of 5 stars
$18.49
+1.3%
$20.00
+8.2%
-42.1%$3.95B$630.72M369.801,039Options Volume
ICUI
ICU Medical
2.2285 of 5 stars
$164.16
+5.2%
$195.00
+18.8%
-26.9%$3.94B$2.28B-52.6214,500News Coverage
Positive News
High Trading Volume
CERE
Cerevel Therapeutics
1.8304 of 5 stars
$24.87
+4.3%
$34.50
+38.7%
-28.9%$3.90BN/A-10.72200Short Interest ↑
PINC
Premier
2.545 of 5 stars
$32.16
+0.2%
$40.70
+26.6%
-10.2%$3.82B$1.43B21.882,600
MDGL
Madrigal Pharmaceuticals
2.2118 of 5 stars
$238.29
-1.0%
$294.75
+23.7%
+133.9%$4.32BN/A-13.8371News Coverage
CERT
Certara
2.0624 of 5 stars
$23.86
+0.3%
$23.14
-3.0%
+5.2%$3.80B$335.64M265.141,204Analyst Report
Short Interest ↓
This page (NYSE:TDOC) was last updated on 3/30/2023 by MarketBeat.com Staff